reports
- Jonathan Moreland
WIRE ENCORE WIRE CORPORATION
VSTM VERASTEM INC
TCBI TEXAS CAPITAL BANCSHARES INC.
SPKE SPARK ENERGY INC-CLASS A
PSA PUBLIC STORAGE
PRGX PRGX GLOBAL
LTS LADENBURG THALMANN FINANCIAL SERVICES INC.
KMPH KEMPHARM INC
58I1 INTREPID POTASH INC.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
HY HYSTER-YALE MATERIALS HANDLING INC. CLASS A
HBI HANESBRANDS INC.
FRED FRED'S INC.
FLKS FLEX PHARMA INC
FLDM FLUIDIGM
FDX FEDEX CORPORATION
FATE FATE THERAPEUTICS INC
FAST FASTENAL COMPANY
DLTR DOLLAR TREE INC.
CRMD CORMEDIX INC.
BDGE BRIDGE BANCORP INC.
GNK GENCO SHIPPING & TRADING LTD.
MLVF MALVERN BANCORP
JMP JMP GROUP LLC
BSET BASSETT FURNITURE INDUSTRIES INC.
CERC CERECOR INC
DSPG DSP GROUP INC.
FBHS
ITI FORTUNE BRANDS HOME & SECURITY INC.
THO ITERIS
ARDC THOR INDUSTRIES INC.
AIRT ARES DYNAMIC CREDIT ALLOCATION
FSBW AIR T INC.
CNBKA FS BANCORP INC
NOVN CENTURY BANCORP INC. CL A
ASPU NOVAN INC
MEET ASPEN GROUP INC
RGRX MEET GROUP
FEIM REGENERX BIOPHARMACEUTICALS INC
KALA FREQUENCY ELECTRONICS INC.
ATNX KALA PHARMACEUTICALS INC.
APPN ATHENEX
ROSE APPIAN
MMAC ROSEHILL RESOURCES
MTEM MMA CAPITAL MANAGEMENT
BBDC LLC
FPAY VOIP INC.
SLCA BARINGS BDC INC.
FUND FLEXSHOPPER
PDI U.S. SILICA HOLDINGS
PCI INC.
AMRK ROYCE FOCUS TRUST
PLAG INC.
PIMCO DYNAMIC INCOME FUND
PIMCO DYNAMIC CREDIT INCOME FUND
A-MARK PRECIOUS METALS
INC.
PLANET GREEN HOLDINGS (N SHARES)
- Jonathan Moreland
LTS LADENBURG THALMANN FINANCIAL SERVICES INC.
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
FLKS FLEX PHARMA INC
FDX FEDEX CORPORATION
ITI ITERIS
SSP THE E.W. SCRIPPS COMPANY
MMAC MMA CAPITAL MANAGEMENT
PLAG LLC
RGT PLANET GREEN HOLDINGS (N SHARES)
ROYCE GLOBAL VALUE TRUST
INC.
Flex Pharma Reports First Quarter 2018 Financial Results
BOSTON--(BUSINESS WIRE)-- Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments in Phase 2 randomized, controlled trials for muscle cramps, spasms and spasticity associated with severe neurological diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) under FDA Fast Track designation, and Charcot-Marie-Tooth (CMT) neuropathy, today reported financial results for the quarter ended March 31, 2018 and provided an update on its clini...
Flex Pharma to Report First Quarter 2018 Financial Results on May 2, 2...
BOSTON--(BUSINESS WIRE)-- Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases such as multiple sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral sclerosis (ALS) under FDA Fast Track designation, announced today that it will report its financial results for the first quarter ended March 31, 2018 on Wednesday, May 2, 2018 before the U.S. financial markets open. The Co...
Flex Pharma Reports Positive Topline Data from Exploratory Phase 2 Tri...
BOSTON--(BUSINESS WIRE)-- Flex Pharma, Inc. (NASDAQ:FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps, spasms and spasticity associated with severe neurological diseases such as multiple sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral sclerosis (ALS) under FDA Fast Track designation today announced positive topline data for FLX-787 from its exploratory Phase 2 trial in MS patients with frequent muscle cramps/spasms and spasticity. “MS pat...
Flex Pharma Reports Year End 2017 Financial Results
BOSTON--(BUSINESS WIRE)-- Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments in Phase 2 randomized, controlled trials for cramps and spasticity associated with severe neurological diseases such as multiple sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral sclerosis (ALS) under FDA Fast Track designation, today reported financial results for the year ended December 31, 2017 and provided an update on its clinical development and corpora...
Flex Pharma to Report Fourth Quarter and Full Year 2017 Results on Mar...
BOSTON--(BUSINESS WIRE)-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases such as multiple sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral sclerosis (ALS) under FDA Fast Track designation, announced today that it will report its financial results for the fourth quarter and year-ended December 31, 2017 on Wednesday, March 7, 2018 ...
Flex Pharma Presenting at BIO CEO on February 13, 2018
BOSTON--(BUSINESS WIRE)-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) and peripheral neuropathies such as Charcot-Marie-Tooth (CMT), today announced that it will present at the BIO CEO conference in New York, NY on February 13, 2018. A live webcast of Flex ...
Enrollment Completed in Flex Pharma’s Phase 2 Exploratory Spasticity...
BOSTON--(BUSINESS WIRE)-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments in Phase 2 randomized, controlled trials for cramps and spasticity associated with severe neurological diseases such as multiple sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral sclerosis (ALS) under FDA Fast Track designation, today announced that it has completed enrollment in its Phase 2 exploratory spasticity stud...
Flex Pharma Reports Third Quarter 2017 Financial Results
BOSTON--(BUSINESS WIRE)-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ:FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments in Phase 2 randomized, controlled trials for cramps and spasticity associated with severe neurological diseases such as multiple sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral sclerosis (ALS) under FDA Fast Track designation, today reported financial results for the quarter ended September 30, 2017 and provided an up...
Flex Pharma Reports Positive Topline Data from Exploratory Phase 2 Tri...
BOSTON--(BUSINESS WIRE)-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ:FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments in Phase 2 randomized, controlled trials for cramps and spasticity associated with severe neurological diseases such as multiple sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral sclerosis (ALS) under FDA Fast Track designation, today announced positive topline data for FLX-787 from its randomized, double-blinded, place...
Flex Pharma to Report Third Quarter 2017 Results on November 6, 2017
BOSTON--(BUSINESS WIRE)-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases such as multiple sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral sclerosis (ALS) under FDA Fast Track designation, announced today that it will report its financial results for the third quarter ended September 30, 2017 on Monday, November 6, 2017...
Flex Pharma Names Dr. Roger Tung to Its Board of Directors
BOSTON--(BUSINESS WIRE)-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases such as multiple sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral sclerosis (ALS) under FDA Fast Track designation, announced today that Roger Tung, Ph.D. has been appointed to its Board of Directors. Dr. Tung is the scientific co-founder of Concer...
Flex Pharma Initiates CMT Phase 2 Trial with FLX-787 in US
BOSTON--(BUSINESS WIRE)-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) and peripheral neuropathies such as Charcot-Marie-Tooth (CMT), today announced that, under its open investigational new drug (IND) application, the Company has initiated a Phase 2 randomized, c...
Flex Pharma Presenting at Upcoming Investor Conferences in September 2...
BOSTON--(BUSINESS WIRE)-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) and peripheral neuropathies such as Charcot-Marie-Tooth (CMT), today announced that it will present at the following upcoming investor conferences in September: The Rodman & Rens...
Flex Pharma Reports Second Quarter 2017 Financial Results
BOSTON--(BUSINESS WIRE)-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases such as multiple sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral sclerosis (ALS) under FDA Fast Track designation, today reported financial results for the quarter ended June 30, 2017 and provided an update on its clinical development and corporate activiti...
Flex Pharma Initiates ALS Phase 2 Trial with FLX-787 in US
BOSTON--(BUSINESS WIRE)-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases such as amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) and peripheral neuropathies such as Charcot-Marie-Tooth (CMT), today announced that, under its open investigational new drug (IND) application, the Company has initiated a Phase 2 randomized, c...
Flex Pharma Names William McVicar President and Chief Executive Office...
BOSTON--(BUSINESS WIRE)-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ:FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with severe neurological diseases including multiple sclerosis (MS), Charcot-Marie-Tooth (CMT) and amyotrophic lateral sclerosis (ALS) under FDA Fast Track designation, today announced that the Board of Directors has appointed William McVicar, Ph.D., as President and Chief Executive Officer of Flex ...
Flex Pharma to Report Second Quarter 2017 Results on August 2, 2017
BOSTON--(BUSINESS WIRE)-- Click to Tweet Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with serious neurological diseases including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Charcot-Marie-Tooth (CMT), announced today that it will report its financial results for the second quarter ended June 30, 2017 on Wednesday, August 2, 2017 before the U.S. financial markets open. T...
FDA Grants Fast Track Designation to Flex Pharma’s FLX-787 for the T...
BOSTON--(BUSINESS WIRE)-- Click to Tweet this News Flex Pharma, Inc. (NASDAQ: FLKS), a clinical-stage biotechnology company that is developing innovative and proprietary treatments for cramps and spasticity associated with serious neurological diseases including amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Charcot-Marie-Tooth (CMT), today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation for the development of FLX-787, the Company’s co-activator of T...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.